Safety and Efficacy of LCL161 in Patients With Solid Tumors

Inclusion criteria

• Solid tumor
• ECOG performance status 0-2
• Life expectancy greater than or equal to 12 weeks
• Must meet certain blood laboratory values
• Must meet criteria for time since the last dose of prior therapy
• Must provide written informed consent to participate in this study

Exclusion criteria

• Active and/or symptomatic brain tumors or brain metastases.
• Patients with unresolved nausea, vomiting, or diarrhea
• Any ongoing severe and/or uncontrolled medical condition that could compromise participation in the study including heart, lung or inflammatory disease
• Any disease that may significantly alter the absorption of the study drug (for example, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or removal of small bowel)
• Patients who are currently receiving treatment with steroids at a certain dose or other immunosuppressive treatment that cannot be stopped prior to starting study drug
• Patients who are currently receiving treatment with certain medications
• Patients who have received radiation therapy or have undergone major surgery within the last 4 weeks
• Women of child-bearing potential who are pregnant or breast feeding.
• Known diagnosis of human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C
• Patients unwilling or unable to follow the protocol

Other protocol-defined inclusion/exclusion criteria may apply